FDA Hits Snooze Button on Neurocrine's Sleep Drug
The FDA initially approved two low-dose versions of Indiplon, but issued a non-approval letter for the higher and longer lasting 15-mg dose.
Indiplon is a drug that acts on a specific site of the GABA-A receptor in the brain believed to be responsible for promoting sleep.
The original application for Indiplon was...
To view the full article, register now.